15.11.2017 • NewsDede WillamsPfizerHisun

Pfizer Sells Stake in Chinese JV with Hisun

(c) doc-stock/Alamy Stock Photo
(c) doc-stock/Alamy Stock Photo

US pharmaceutical giant Pfizer has divested its 49% stake in Hisun-Pfizer Pharmaceuticals its Chinese joint venture with Zhejiang Hisun Pharma. As part of the plan, Sapphire I Holdings, which is indirectly controlled by private equity firm Hillhouse Capital, will acquire Pfizer’s shareholding.

Hisun-Pfizer Pharmaceuticals was founded in 2012 to develop, manufacture and sell branded generic drugs in China and neighboring regions. Its portfolio includes branded generics covering cardiovascular disease, infectious disease, oncology, mental health and other therapeutic areas.

According to press reports, the US drugmaker had been considering exiting since the end of last year, when the jv’s lead product, Tazocin, an injectable containing piperacillin and tazobactam, began experiencing supply issues due to a manufacturing upgrade at Pfizer’s plant in Italy, and at the same time the US Food and Drug Administration (FDA) issued an import alert over output of Hisun’s API plant.

In any case, Pfizer is seen to be keen to establish itself as an independent player in the Chinese market.

Through the arrangement with its US partner, API manufacturer Hisun was able move into the finished drugs market for the first time. Under the severance terms, Pfizer said it will continue to provide technical, manufacturing and regulatory support services to the jv as well as transferring technology to ensure that products it previously supplied can continue to be manufactured in China. The transfer process is expected to take about five years.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.